Role of circulating tumour cells (CTCs) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).
biomarker
circulating tumour cells
head and neck cancer
recurrent
response
Journal
Ecancermedicalscience
ISSN: 1754-6605
Titre abrégé: Ecancermedicalscience
Pays: England
ID NLM: 101392236
Informations de publication
Date de publication:
2023
2023
Historique:
received:
06
02
2023
medline:
3
8
2023
pubmed:
3
8
2023
entrez:
3
8
2023
Statut:
epublish
Résumé
Liquid biopsy is emerging as a non-invasive tool, providing a personalized snapshot of a primary and metastatic tumour. It aids in detecting early metastasis, recurrence or resistance to the disease. We aimed to assess the role of circulating tumour cells (CTCs) as a predictive biomarker in recurrent/metastatic head and neck cancer (head and neck squamous cell carcinoma (HNSCC)). Thirty-five patients receiving palliative chemotherapy underwent blood sampling [2 mL in Ethylenediaminetetraacetic acid (EDTA) vial] at baseline and at 3 months intervals. The CTCs were isolated and evaluated using anti-epithelial cell adhesion molecule antibody-based enrichment using the OncoDiscover platform. CTCs isolated from 80% of patients ( This study highlights the utility of CTC as a disease progression-monitoring tool in recurrent HNSCC patients. Our findings suggest the potential clinical utility of CTC and the need for exploration in upfront settings of the disease as well (NCT: CTRL/2020/02/023378).
Sections du résumé
Background
UNASSIGNED
Liquid biopsy is emerging as a non-invasive tool, providing a personalized snapshot of a primary and metastatic tumour. It aids in detecting early metastasis, recurrence or resistance to the disease. We aimed to assess the role of circulating tumour cells (CTCs) as a predictive biomarker in recurrent/metastatic head and neck cancer (head and neck squamous cell carcinoma (HNSCC)).
Methodology
UNASSIGNED
Thirty-five patients receiving palliative chemotherapy underwent blood sampling [2 mL in Ethylenediaminetetraacetic acid (EDTA) vial] at baseline and at 3 months intervals. The CTCs were isolated and evaluated using anti-epithelial cell adhesion molecule antibody-based enrichment using the OncoDiscover platform.
Results
UNASSIGNED
CTCs isolated from 80% of patients (
Conclusion
UNASSIGNED
This study highlights the utility of CTC as a disease progression-monitoring tool in recurrent HNSCC patients. Our findings suggest the potential clinical utility of CTC and the need for exploration in upfront settings of the disease as well (NCT: CTRL/2020/02/023378).
Identifiants
pubmed: 37533950
doi: 10.3332/ecancer.2023.1578
pii: can-17-1578
pmc: PMC10393317
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1578Informations de copyright
© the authors; licensee ecancermedicalscience.
Déclaration de conflit d'intérêts
The authors have no conflict of interest.
Références
Ann Oncol. 2014 Oct;25(10):2042-2047
pubmed: 25057171
World J Otorhinolaryngol Head Neck Surg. 2016 Jul 21;2(2):109-116
pubmed: 29204555
Ecancermedicalscience. 2022 Sep 29;16:1451
pubmed: 36405947
Breast Cancer Res Treat. 2017 Jan;161(1):83-94
pubmed: 27771841
Oral Surg Oral Med Oral Pathol Oral Radiol. 2022 Jul;134(1):73-83
pubmed: 35595620
Oncol Rep. 2020 May;43(5):1525-1535
pubmed: 32323844
ESMO Open. 2020 Nov;5(6):e000944
pubmed: 33148620
PLoS One. 2015 Jul 17;10(7):e0132901
pubmed: 26186556
Support Care Cancer. 2016 Apr;24(4):1595-602
pubmed: 26386707
Front Pharmacol. 2017 Feb 01;8:35
pubmed: 28203204
Technol Cancer Res Treat. 2021 Jan-Dec;20:1533033821990037
pubmed: 33641530
Clin Cancer Res. 2019 Oct 15;25(20):6089-6097
pubmed: 31358544
Cancers (Basel). 2019 Mar 15;11(3):
pubmed: 30875950
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancers (Basel). 2021 Apr 14;13(8):
pubmed: 33919778
Arch Otolaryngol Head Neck Surg. 2010 Dec;136(12):1274-9
pubmed: 21173379
J Mater Chem B. 2021 Apr 7;9(13):2946-2978
pubmed: 33480960
Nat Rev Cancer. 2008 May;8(5):329-40
pubmed: 18404148
Sci Rep. 2017 Feb 15;7:42517
pubmed: 28198401